ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Increased Expression of TICRR Predicts Poor Clinical Outcomes: A Potential Therapeutic Target for Papillary Renal Cell Carcinoma

Xia, Shuang; Lin, Yan; Lin, Jiaqiong; Li, Xiaoyong; Tan, Xuexian; Huang, Zena*广东省人民医院; 广东省心血管病研究所; 广州医学院; 南方医科大学
Frontiers in Genetics2021-1-11DOI: 10.3389/fgene.2020.605378
7被引5阅读
引用收藏
分享

摘要

Background: Papillary renal cell carcinoma (PRCC), although the second-most common type of renal cell carcinoma, still lacks specific biomarkers for diagnosis, treatment, and prognosis. TopBP1-interacting checkpoint and replication regulator (TICRR) is a DNA replication initiation regulator upregulated in various cancers. We aimed to evaluate the role of TICRR in PRCC tumorigenesis and prognosis. @@@ Methods: Based on the Kidney Renal Papillary cell carcinoma Project (KIRP) on The Cancer Genome Atlas (TCGA) database, we determined the expression of TICRR using the Wilcoxon rank sum test. The biological functions of TICRR were evaluated using the Metascape database and Gene Set Enrichment Analysis (GSEA). The association between TICRR and immune cell infiltration was investigated by single sample GSEA. Logistic analysis was applied to study the correlation between TICRR expression and clinicopathological characteristics. Finally, Cox regression analysis, Kaplan-Meier analysis, and nomograms were used to determine the predictive value of TICRR on clinical outcomes in PRCC patients. @@@ Results: TICRR expression was significantly elevated in PRCC tumors (P < 0.001). Functional annotation indicated enrichment with negative regulation of cell division, cell cycle, and corresponding pathways in the high TICRR expression phenotype. High TICRR expression in PRCC was associated with female sex, younger age, and worse clinical stages. Cox regression analysis revealed that TICRR was a risk factor for overall survival [hazard ratio (HR): 2.80, P = 0.002], progression-free interval (HR: 2.86, P < 0.001), and disease-specific survival (HR: 7.03, P < 0.001), especially in patients with male sex, age below 60 years, clinical stages II-IV and clinical T stage T1-T2. @@@ Conclusion: Increased TICRR expression in PRCC might play a role in tumorigenesis by regulating the cell cycle and has prognostic value for clinical outcomes.

学科与关键词

关键词
TICRRpapillary renal cell carcinomaclinical outcomeTreslinimmune infiltration
相关
加载中…
  • miR-21-5p/PRKCE axis implicated in immune infiltration and poor prognosis of kidney renal clear cell carcinoma
    Wang, Jinxiang; Jin, Jie; Liang, Yanling; Zhang, Yihe; Wu, Nisha; Fan, Mingming; Zeng, Fangyin*; Deng, Fan*Frontiers in Genetics, 2022, 13: 978840.
  • Decreased CDKL2 Expression in Clear Cell Renal Cell Carcinoma Predicts Worse Overall Survival
    Chen, Zhan; Lv, Yan; He, Lu; Wu, Shunli; Wu, Zhuang*Frontiers in Molecular Biosciences, 2022, 8: 657672.被引 2
  • High Hepcidin expression predicts poor prognosis in patients with clear cell renal cell carcinoma
    Tang, Yuting; Ge, Shengdong; Zheng, Xiao*; Zheng, Jiejiao*Diagnostic Pathology, 2022, 17(1): 100.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Genetics
发表日期
2021-01-11
卷期
第 11 卷
页码
605378
DOI
10.3389/fgene.2020.605378
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
Natural Science Foundation of Guangdong Province [2018A030310016]; Guangdong Provincial Medical Science Foundation [A2018110]; Lab Opening-up Project for college students of Guangzhou Medical University

作者

  • X

    Xia, Shuang (第一作者)

    guangdong cardiovasc inst · guangdong prov peoples hosp

  • L

    Lin, Yan

    guangzhou med univ

查看全部 6 位作者收起作者
  • L

    Lin, Jiaqiong

    southern med univ

  • L

    Li, Xiaoyong

    guangzhou med univ

  • T

    Tan, Xuexian

    guangzhou med univ

  • H

    Huang, Zena (通讯)

    guangdong prov peoples hosp

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417